Mycobacterium septicum is a rarely identified nontuberculous mycobacterium capable of causing infections in both healthy and immunocompromised individuals. Only a few cases of M. septicum infections have been reported, which makes recognizing corresponding clinical disease more challenging for clinicians. Antimicrobial susceptibility profiles for this organism are not well described, and corresponding optimal therapeutic regimens have not been established. We report a tertiary care center’s experience with M. septicum from 2014 to 2020. Twelve adult patients with positive cultures for M. septicum were identified. Most cases were identified from sputum samples of individuals with underlying lung disease. Most cases involving M. septicum isolation in culture were not felt to be clinically significant. Two cases were considered possible infections, while only one case was considered a definite infection that required antimicrobial treatment. All M. septicum isolates were susceptible in vitro to amikacin, ciprofloxacin, imipenem, linezolid, moxifloxacin, and trimethoprim-sulfamethoxazole. Isolates were universally resistant to clarithromycin and doxycycline. The isolation of M. septicum in culture is uncommon and requires clinical correlation to determine its clinical relevance and need for treatment. Susceptibility testing should be performed to guide therapy.

中文翻译：

---

败血分枝杆菌：三级医院和参考实验室的6年临床经验。

败血分枝杆菌是一种罕见的非结核分枝杆菌，能够在健康和免疫功能低下的个体中引起感染。仅报告了败血支原体感染的几例，这使得识别相应的临床疾病对临床医生而言更具挑战性。对该微生物的抗药性没有得到很好的描述，并且尚未建立相应的最佳治疗方案。我们报告了一家三级医疗中心从2014年到2020年的败血支原体的经验。确定了12名成年菌支原体为阳性的成年患者。大多数病例是从具有潜在肺部疾病的患者的痰液样本中鉴定出来的。大多数案件涉及分离培养物中的败血支原体不具有临床意义。有2例被认为是可能的感染，而只有1例被认为是需要抗菌治疗的明确感染。所有败血支原体的分离株在体外均对阿米卡星，环丙沙星，亚胺培南，利奈唑胺，莫西沙星和甲氧苄啶-磺胺甲恶唑敏感。分离株普遍对克拉霉素和强力霉素有抗性。在培养物中分离败血支原体并不常见，需要临床相关以确定其临床相关性和治疗需求。应进行药敏试验以指导治疗。